Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fibrin sealant - Grifols

Next Previous
Drug Profile

Fibrin sealant - Grifols

Alternative Names: FS Grifols; Human fibrinogen/human thrombin - Grifols; VeraSeal; VISTASEALTM

Latest Information Update: 08 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grifols
  • Class Acute-phase proteins; Adhesives; Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Serine endopeptidases
  • Mechanism of Action Fibrinogen replacements; Thrombin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Surgical blood loss

Most Recent Events

  • 20 May 2022 Grifols Therapeutics completes a phase III trial in Surgical blood loss (Adjunctive treatment, In adolescents, In infants, In children) in USA, Bulgaria, France, Hungary, Romania, Serbia, and United Kingdom (Topical) (NCT03461406)
  • 03 Mar 2021 Fibrin sealant is still in phase III trial for Surgical blood loss (In adolescents, In children, In infants) in USA, Bulgaria, Hungary, France, Romania, Serbia and United Kingdom (Topical) (NCT03461406)
  • 16 Mar 2018 Grifols Therapeutics plans a phase III trial for Surgical blood loss (Adjunctive treatment, In infants, In children, In adolescents) in March 2018 (NCT03461406)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top